이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Kringle Pharma 관리

관리 기준 확인 1/4

Kringle Pharma's CEO는 Kiichi Adachi, Dec2016 에 임명되었습니다 의 임기는 7.5 년입니다. 는 ¥ 59.96M 가치에 해당하는 회사 주식의 1.12% 직접 소유합니다. 59.96M. 경영진과 이사회의 평균 재임 기간은 각각 1.5 년과 5.5 년입니다.

주요 정보

Kiichi Adachi

최고 경영자

n/a

총 보상

CEO 급여 비율	n/a
CEO 임기	7.6yrs
CEO 소유권	1.1%
경영진 평균 재임 기간	1.6yrs
이사회 평균 재임 기간	5.6yrs

최근 관리 업데이트

Recent updates

Here's Why We're Not Too Worried About Kringle Pharma's (TSE:4884) Cash Burn Situation

Jun 15

We Think Kringle Pharma (TSE:4884) Can Afford To Drive Business Growth

Mar 02

CEO

Kiichi Adachi (57 yo)

7.6yrs

테뉴어

Kiichi Adachi, Ph D., has been President at Kringle Pharma, Inc since December 27, 2016. Kiichi Adachi serves as a Director of Kringle Pharma, Inc. since December 2005.Kiichi Adachi was Research Scientist...

리더십 팀

이름	위치	테뉴어	보상	소유권
Kiichi Adachi	President & Director	7.6yrs	데이터 없음	1.12% ¥ 75.1m
Tomoya Shimojo	Chief Financial Officer & Director of Accounting and Corporate Planning	no data	데이터 없음	데이터 없음
Kunio Matsumoto	Chief Scientific Officer	no data	데이터 없음	데이터 없음
Koichi Murakami	GM of Corporate Planning Management Department & Director	no data	데이터 없음	데이터 없음
Daichika Hayata	GM of Pharmaceutical Development and Pharmaceutical Affairs Department & Director	1.6yrs	데이터 없음	데이터 없음
Yoshiyuki Kayano	Director & GM of Quality Assurance Department	less than a year	데이터 없음	데이터 없음

1.6yrs

평균 재임 기간

52yo

평균 연령

경험이 풍부한 관리: 4884 의 관리팀은 경험 (평균 재직 기간 1.5 년)으로 간주되지 않으므로 새로운 팀을 추천합니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Kiichi Adachi	President & Director	18.6yrs	데이터 없음	1.12% ¥ 75.1m
Koichi Murakami	GM of Corporate Planning Management Department & Director	2.6yrs	데이터 없음	데이터 없음
Daichika Hayata	GM of Pharmaceutical Development and Pharmaceutical Affairs Department & Director	1.6yrs	데이터 없음	데이터 없음
Yoshiyuki Kayano	Director & GM of Quality Assurance Department	less than a year	데이터 없음	데이터 없음
Kohichiro Yoshino	Independent Outside Director	5.6yrs	데이터 없음	데이터 없음
Akihiro Tomoyasu	Part Time Director	7.6yrs	데이터 없음	데이터 없음
Kazuto Ninomiya	Audit & Supervisory Board Member	5.6yrs	데이터 없음	데이터 없음
Masahiro Motokawa	Audit & Supervisory Board Member	5.6yrs	데이터 없음	데이터 없음
Yosuke Yamaguchi	Audit & Supervisory Board Member	5.6yrs	데이터 없음	데이터 없음
Masato Fukui	Independent Outside Director	3.6yrs	데이터 없음	데이터 없음

5.6yrs

평균 재임 기간

52yo

평균 연령

경험이 풍부한 이사회: 4884 의 이사회는 경험(평균 재직 기간 5.5 년)으로 간주됩니다.

Kringle Pharma 관리

관리 기준 확인 1/4

주요 정보

최근 관리 업데이트

Kringle Pharma, Inc., Annual General Meeting, Dec 23, 2022

No independent directors

No independent directors

Recent updates

Here's Why We're Not Too Worried About Kringle Pharma's (TSE:4884) Cash Burn Situation

Second quarter 2024 earnings released: JP¥30.66 loss per share (vs JP¥29.35 loss in 2Q 2023)

We Think Kringle Pharma (TSE:4884) Can Afford To Drive Business Growth

First quarter 2024 earnings released: JP¥29.45 loss per share (vs JP¥29.18 loss in 1Q 2023)

Kringle Pharma, Inc. Provides Earnings Guidance for the Fiscal Year Ending September 30, 2024

Kringle Pharma, Inc. to Report Q1, 2024 Results on Feb 09, 2024

Full year 2023 earnings released: JP¥158 loss per share (vs JP¥68.16 loss in FY 2022)

New minor risk - Shareholder dilution

Kringle Pharma, Inc. to Report Fiscal Year 2023 Results on Nov 13, 2023

Kringle Pharma, Inc. Provides Earnings Guidance for the Fiscal Year Ending September 30, 2023

Third quarter 2023 earnings released: JP¥48.79 loss per share (vs JP¥2.57 profit in 3Q 2022)

New minor risk - Shareholder dilution

Kringle Pharma, Inc. Provides Earnings Guidance for the Fiscal Year Ending September 30, 2023

First half 2023 earnings released: JP¥58.52 loss per share (vs JP¥70.08 loss in 1H 2022)

First quarter 2023 earnings released: JP¥29.18 loss per share (vs JP¥29.02 loss in 1Q 2022)

Kringle Pharma, Inc. Announces First Patient Enrollment in Phase III Clinical Study for the Treatment of Vocal Fold Scar

Kringle Pharma, Inc. Provides Update on Progress of Phase 3 Clinical Trial in Patients with Acute Spinal Cord Injury

Full year 2022 earnings released: JP¥68.16 loss per share (vs JP¥72.47 loss in FY 2021)

Kringle Pharma, Inc. to Report Q1, 2023 Results on Feb 10, 2023

Kringle Pharma, Inc. Provides Consolidated Earnings Guidance for Year Ending September 30, 2023

Kringle Pharma, Inc. Announces Initiation of Phase III Study of HGF in Vocal Fold Scar

Full year 2022 earnings released: JP¥68.16 loss per share (vs JP¥72.47 loss in FY 2021)

Kringle Pharma, Inc., Annual General Meeting, Dec 23, 2022

No independent directors

Kringle Pharma, Inc. Submits Clinical Trial Application

Kringle Pharma, Inc. Announces Jointly File A Patent Application with Keio University

Kringle Pharma, Inc. to Report Fiscal Year 2022 Results on Nov 14, 2022

Kringle Pharma, Inc. Provides Earnings Guidance for the Year Ending September 30, 2022

Third quarter 2022 earnings released: EPS: JP¥2.57 (vs JP¥12.50 loss in 3Q 2021)

Kringle Pharma, Inc. Updates on the Investigator-initiated Phase 2 Study in Patients with ALS

Kringle Pharma, Inc. Provides Earnings Guidance for the Fiscal Year Ending September 30, 2022

Second quarter 2022 earnings released: JP¥40.79 loss per share (vs JP¥12.50 loss in 2Q 2021)

Kringle Pharma, Inc. Provides an Update on Progress of Phase 3 Clinical Trial in Patients with Acute Spinal Cord Injury

No independent directors

Kringle Pharma, Inc. Provides Earnings Guidance for the Fiscal Year Ending September 30, 2022

First quarter 2022 earnings: Revenues and EPS in line with analyst expectations

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Kringle Pharma, Inc. Provides Earnings Forecast for the Fiscal Year Ending September 30, 2022

Kringle Pharma, Inc Announces Last Patient Out in Phase 2 Study of Kp-100It for the Treatment of Als

Kringle Pharma, Inc. Provides Earnings Guidance for the Fiscal Year Ending September 30, 2021

Kringle Pharma, Inc. to Report Q2, 2021 Results on May 14, 2021

Kringle Pharma, Inc. to Report Q1, 2021 Results on Feb 12, 2021

Kringle Pharma, Inc. has completed an IPO in the amount of ¥580 million.

CEO

테뉴어

리더십 팀

평균 재임 기간

평균 연령

이사회 구성원

평균 재임 기간

평균 연령